Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Large Molecule Therapeutics

Development of Novel Antibody–Camptothecin Conjugates

Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter and Scott C. Jeffrey
Ryan D. Lyski
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren B. Bou
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uland Y. Lau
2Neoleukin Therapeutics, Inc., Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Uland Y. Lau
David W. Meyer
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia H. Cochran
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole M. Okeley
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim K. Emmerton
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francisco Zapata
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica K. Simmons
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther S. Trueblood
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Esther S. Trueblood
David J. Ortiz
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margo C. Zaval
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie M. Snead
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Jin
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren M. Farr
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maureen C. Ryan
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter D. Senter
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott C. Jeffrey
1Seagen Inc., Bothell, Seattle, Washington.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sjeffrey@seagen.com
DOI: 10.1158/1535-7163.MCT-20-0526 Published February 2021
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Camptothecin payloads and linkers.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    ADC pharmacokinetic and physiochemical measurements. A, Size-exclusion chromatography traces for CPT–Lb and CPT–Lc cAC10 ADCs. B, Hydrophobic interaction chromatography. cAC10, cAC10—CPT–Lb, and cAC10-DT were injected onto a Butyl HIC NPR column (2.5 μm, 4.6 mm × 3.5 cm, Tosoh Bioscience, PN 14947) at 25°C and eluted with a 12-minute linear gradient from 0% to 100% B at a flow rate of 0.8 mL/min (Mobile Phase A, 1.5 mol/L ammonium sulfate in 25 mmol/L potassium phosphate, pH 7; Mobile Phase B, 25 mmol/L potassium phosphate, pH 7, 25% isopropanol). C, Kupffer cell uptake assay. Kupffer cells were incubated with AlexaFluor 647-labeled ADCs at a concentration of 0.1 mg/mL in cell culture media for 24 hours. ADC uptake into cells determined by measuring mean fluorescent intensity (MFI), D, Pharmacokinetic profile of h00 mAb (non–cross-reactive), and h00–CPT–Lb in rats. Rats were injected with 1 mg/kg of parental h00 mAb or h00–CPT–Lb ADC. Samples from scheduled blood draws were obtained, and the h00 antibody and h00–CPT–Lb ADC were captured from plasma via a biotin-conjugated murine anti-human light chain kappa mAb and streptavidin-coated beads. The h00 antibody and ADC were quantified via ELISA using an AF647-anti–human kappa detection reagent.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    In vivo xenograft studies. A and B (data from separate studies), Activity of cAC10 ADCs based on CPT–Lb, CPT–Lc, and GT drug-linkers in L540cy HD xenograft model. C, Comparison of cAC10–CPT–Lc and DT ADCs in CD30-low L428 HD model. D, Comparison of cAC10–CPT–Lc and cAC10-DT in Karpas 299 (CD30-positive)/Karpas BVR (CD30-negative) bystander killing activity model. All experiments were single-dose studies.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Characterization of CPT drug release and biochemical potency. A, CD30-positive Karpas 299 and L540cy cells were treated with the cAC10–CPT–Lc ADC (100 ng/mL) for 24 hours, followed by extraction of released drug from pelleted cells and supernatant, and drug quantitation by LC-MS/MS. B, Supercoiled DNA-topoisomerase 1 complex trapping with CPT payloads CPT1 and CPT2.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Rat toxicology results: hematology and weight. A, Absolute neutrophil (x103/μL). B, Absolute reticulocyte (cells/μL). C, Platelet counts (x103/μL) for q7dx4 treatment of h00–CPT–Lb at 60 mg/kg/dose, compared with vehicle (PBS) control animals. D, The percentage of animal weight loss for 10, 30, and 60 mg/kg/dose of h00–CPT–Lb, q7dx4, compared with vehicle control.

Tables

  • Figures
  • Additional Files
  • Table 1.

    CPT payload (IC50 nmol/L) and ADC (IC50 ng/mL) in vitro potency on CD30-positive HD and ALCL cancer cell lines.

    CD30-positive cancer cell lines (CD30 expression)
    L540cyKarpasL-428DELDEL/BVR
    HDALCLHDALCLALCL
    Payloads(400K)(320K)(70K)(285K)(180K)
    CPT11220.71
    CPT224401604230
    MMAE0.20.110.23
    ADCs
    cAC10–CPT–La>1K>1K>1K34
    h00–CPT–La>1K>1K>1K>1K>1K
    cAC10–CPT–Lb11>1K13
    h00–CPT–Lb>1K>1K>1K>1K>1K
    cAC10–CPT–Lc12>1K13
    h00–CPT–Lc>1K>1K>1K930>1K
    cAC10–DT26>1K>1K716
    h00–DT>1K>1K>1K>1K>1K
    cAC10–GT791608502027
    h00–GT461608201925

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    • Supplementary Data - Table S1, Table S2, Table S3, Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7
PreviousNext
Back to top
Molecular Cancer Therapeutics: 20 (2)
February 2021
Volume 20, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Development of Novel Antibody–Camptothecin Conjugates
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Development of Novel Antibody–Camptothecin Conjugates
Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter and Scott C. Jeffrey
Mol Cancer Ther February 1 2021 (20) (2) 329-339; DOI: 10.1158/1535-7163.MCT-20-0526

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of Novel Antibody–Camptothecin Conjugates
Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter and Scott C. Jeffrey
Mol Cancer Ther February 1 2021 (20) (2) 329-339; DOI: 10.1158/1535-7163.MCT-20-0526
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authors' Disclosures
    • Authors' Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Bispecific Antibody for the Treatment of Ovarian Cancer
  • Mechanisms of Resistance to PBD and PBD-based ADCs
  • Exosomes Expressing IL12 Promote Antitumor Immunity
Show more Large Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement